GlassScriptPhysician profile
Howard I Hyman
NPI 1316916299
$1,008.67
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $266 · 2021: $125 · 2022: $98.18.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $336.07 | 2019-2021 | |
| Zyla Life Sciences, INC. | $125.85 | 2019 | |
| Cardiovascular Systems INC. | $114.62 | 2019 | |
| Smith+Nephew, INC. | $77.79 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.35 | 2019-2022 | |
| Sebela Pharmaceuticals INC. | $69.80 | 2019-2022 | |
| Bioventus LLC | $43.49 | 2019-2020 | |
| Royal Biologics, INC. | $23.36 | 2021 | |
| Kerecis Limited | $21.84 | 2020 | |
| Bard Peripheral Vascular, INC. | $19.99 | 2019 | |
| Mayne Pharma Commercial LLC | $18.52 | 2022 | |
| Zimmer Biomet Holdings, INC. | $17.16 | 2020 | |
| Journey Medical Corporation | $14.97 | 2020 | |
| Abbvie INC. | $13.13 | 2022 | |
| Heron Therapeutics, INC. | $12.74 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $11.59 | 2019 | |
| Grt US Holding, INC. | $10.40 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.